Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Istituto Nazionale Tumori Regina Elena, Roma

Centre Hospitalier Universitaire Vaudois, Lausanne

Hôpitaux Universitaire de Genève, Geneva

Universitätsspital Zürich, Zurich

Columbia University Medical Center, New York

Memorial Sloan Kettering Cancer Center, New York

Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin

Hopitaux de La Timone, Marseille

University of Pittsburgh Hillman Cancer Center, Pittsburgh

University of Pennsylvania, Philadelphia

Istituto Clinico Humanitas, Rozzano

Universitätsklinikum Hamburg Eppendorf, Hamburg

John Hopkins Cancer Center, Baltimore

Duke University Medical Center, Durham

Hospital Universitario Ramon y Cajal, Madrid

Hospital Universitario 12 de Octubre, Madrid

Medical University of South Carolina, Charleston

Mayo Clinic Jacksonville, Jacksonville

Sylvester Comprehensive Cancer Center - University of Miami Hospital and Clinics, Miami

Istituto Oncologico Veneto - I.R.C.C.S., Padua

University of Alabama at Birmingham, Birmingham

Tennessee Oncology, Nashville

Ospedale Bellaria, Bologna

University of Kentucky, Lexington

Ohio State University Comprehensive Cancer Center, Columbus

Universitätsklinikum Essen, Essen

Indiana University Medical Center, Indianapolis

University of Michigan Comprehensive Cancer Center, Ann Arbor

Henry Ford Hospital, Detroit

Rabin Medical Center, Petah Tikva

Chaim Sheba Medical Center, Ramat Gan

Metro Minnesota Community Oncology, Minneapolis

Mayo Comprehensive Cancer, Rochester

Centre Hospitalier Universitaire de Lille, Lille

Northwestern University, Chicago

University of Chicago, Chicago

Washington University School of Medicine, St Louis

University of Kansas Medical Center, Kansas City

Klinikum Mannheim Universitätsklinikum, Mannheim

Universitätsklinikum Heidelberg, Heidelberg

Hôpital Pierre Wertheimer, Lyon

Hospitalier Pitié Salpétrière, Paris

Baylor University Medical Center, Dallas

University of Texas Southwestern Medical Center, Dallas

MD Anderson Cancer Center, Houston

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora

The University of Utah, Huntsman Cancer Hospital, Salt Lake City

UCLA Oncology Center, Los Angeles

City of Hope, Duarte

Hadassah Medical Center, Jerusalem

University of California San Diego, La Jolla

University of California Irvine - Hospital, Orange

University of California San Francisco, San Francisco

Stanford Cancer Center, Stanford

Oregon Health and Science University, Portland

Seattle Cancer Care Alliance, Seattle

Tel Aviv Sourasky Medical Center, Tel Aviv

Yale University, Yale Cancer Center, New Haven

Maine Medical Partners Neurology, Scarborough

Tufts Medical Center, Boston

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston

BC Cancer Agency, Vancouver

London Health Sciences Centre, London

Sunnybrook Health Sciences Centre, Toronto

Princess Margaret Hospital, Toronto

McGill University Health Center, Montreal

Nagoya University Hospital, Nagoya

Fujita Health University Hospital, Toyoake

Hiroshima University Hospital, Minami-Ku

The University of Tokyo Hospital, Bunkyō-Ku

National Cancer Center Hospital, Chuo Ku

Kumamoto University Hospital, Kumamoto

University Hospital, Kyoto Prefectural University of Medicine, Kyoto

Kyoto University Hospital, Kyoto

Okayama University Hospital, Okayama

Haaglanden MC, Antoniushove, Leidschendam

Erasmus Medical Center, Rotterdam

Universitair Medisch Centrum Utrecht, Utrecht

Hospital Universitario Vall d'Hebrón, Barcelona

Freeman Hospital, Newcastle upon Tyne

The Royal Marsden NHS Foundation Trust, Sutton

Western General Hospital Edinburgh - PPDS, Edinburgh

The Christie NHS Foundation Trust, Manchester